Short Interest in Immatics (NASDAQ:IMTXW) Rises By 7.1%

Immatics (NASDAQ:IMTXW) was the target of a significant growth in short interest during the month of September. As of September 15th, there was short interest totalling 1,500 shares, a growth of 7.1% from the August 31st total of 1,400 shares. Based on an average daily trading volume, of 1,200 shares, the days-to-cover ratio is presently 1.3 days.

Immatics Price Performance

Shares of IMTXW stock remained flat at $2.60 during trading hours on Monday. Immatics has a 52 week low of $1.60 and a 52 week high of $4.14. The firm’s 50-day simple moving average is $2.68 and its 200 day simple moving average is $2.81.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.